The X-linked disease retinoschisis is caused by mutations in the RS1 gene encoding retinoschisin, most commonly missense mutations leading to a lack of secretion of functional protein. One potential approach to treat this disease would be the introduction of the wild-type protein by gene therapy in affected individuals. Retinoschisin normally forms homo-octamers, so co-expression of the wild-type protein with the mutant could result in their co-assembly. In the present study, we show that retinoschisin assembles into an octamer before transport from the endoplasmic reticulum and that co-assembly of wild-type and mutant protein can occur when they are co-expressed in the same cell. This coassembly results in the retention of some, but not all, expressed wild-type retinoschisin. Moreover, when the wild-type protein is expressed with a missense mutant that is normally secreted, co-assembly occurs resulting in the secretion of a heterogeneous mixture of oligomers. Missense mutations of retinoschisin which cause intracellular retention also lead to an unfolded protein response. However, this is not sufficient to decrease cell viability suggesting that the pathology of the disease is not likely to be linked to programmed cell death.
INTRODUCTION
The ER (endoplasmic reticulum) of mammalian cells acts as a quality-control checkpoint in the secretion of proteins, orchestrating correct folding and assembly and preventing the secretion of incorrectly folded or assembled molecules [1] . During the folding of proteins in normal healthy tissues, this checkpoint is essential to both prevent the secretion of potentially toxic misfolded proteins and conserve energy resources by degrading and recycling protein subunits of multi-subunit proteins that are made in excess. ER quality control also plays a crucial role in certain disease states (e.g. cystic fibrosis, emphysema and diabetes) where mutations in single proteins can lead to misfolding and intracellular retention, thereby preventing secretion of the protein and hence cause loss of function [2] . Our understanding of the general mechanisms underlying the retention of misfolded proteins within the ER is limited to a wellcharacterized system for the retention of glycoproteins by the ER lectins calnexin and calreticulin and a realization that several ER-resident proteins such as BiP (immunoglobulin heavy-chainbinding protein) can bind to exposed hydrophobic sequences in misfolded proteins and thereby retain these proteins within the ER [3] . Clearly, if we are to develop rational therapies for such diseases, our knowledge in this area needs to be strengthened, particularly when it comes to soluble non-glycoproteins linked to specific disease pathologies.
The X-linked disease retinoschisis is one such disease that results from inactivating mutations of the RS1 gene which encodes retinoschisin [4, 5] . Mutations are often missense, leading to a lack of secretion of functional protein retinoschisin and resulting in splitting of the inner retinal layers, causing visual deterioration in childhood [6] . Retinoschisin is a soluble non-glycosylated protein that is normally secreted from photoreceptor and bipolar cells of the retina [7] . Previously, it was postulated to have a role in cell adhesion as it consists almost entirely of a single discoidin domain [8] ; however, more recently it has been shown to associate with L-VGCC (L-type voltage-gated channel) α1D subunits, regulating channel activity in a circadian manner [9] and the Na + /K + -ATPase-SARM1 [sterile α and TIR (Toll/interleukin-1 receptor) motif-containing 1] complex [10] . Over 133 mutations in the gene coding for retinoschisin (RS1) are associated with X-linked retinoschisis, the majority being missense substitutions [5, 11] . It is likely that these lead to loss of function as the disease is also caused by nonsense, deletions, insertions and splice-site mutations. Many of these mutations lead to intracellular retention of the mutated proteins, presumably through aberrant folding or assembly [6, 8] . Retinoschisis is therefore an excellent example of a disease that is caused by the lack of secretion of a functional protein.
Current efforts to understand the molecular basis for retinoschisis have focused on an evaluation of the consequences of specific point mutations on disulfide bond formation and secretion of retinoschisin [8, 12] . Retinoschisin is a 24 kDa protein that contains ten cysteine residues which form both intra-and interchain disulfide bonds and is normally secreted as a covalently linked homooctamer [12] . Formation of an octamer stabilized by interchain disulfide bonds is essential for function [12] , and in this context it is interesting to note that 25 % of the known missense mutations involve either a loss or gain of a cysteine residue. Studies to date have revealed that there are three major causes of loss-of-function of retinoschisin resulting from the missense mutations analysed; namely, mutations that prevent protein secretion, mutations that prevent oligomerization, but do not prevent secretion, and mutations that do not prevent oligomerization or secretion, but presumably prevent interactions with partner proteins [6, 8] .
In an effort to understand the disease pathology in more detail, two knockout mouse models were created, both of which mimic the features of human X-linked retinoschisis [13, 14] . When the RS1 gene was delivered to an adult knockout mouse, the disease symptoms were reversed providing hope that delivery of wildtype RS1 to patients affected by retinoschisis may be an effective therapy [14, 15] . However, neither disease model is equivalent to the human patient, as the mice were knockout models with no Rs1 gene expression, whereas affected individuals will be expressing mutant protein which may interfere with the ectopically expressed retinoschisin. A previous study has shown that wild-type protein can be secreted from cells when co-expressed with mutant proteins [16] . However, this study did not evaluate the ability of the mutant protein to co-assemble with wild-type within the cell. In the present study, we address where oligomerization of retinoschisin occurs, whether co-assembly of wild-type and mutant protein occurs within cells and whether the pathology of the disease can be explained by the retention of mutant protein causing an UPR (unfolded protein response) leading to cell death.
MATERIALS AND METHODS

Generation of epitope-tagged RS1 cDNA constructs
PCR products containing the complete coding sequence for wildtype retinoschisin and the C59S and C110Y retinoschisin mutants were amplified from cDNA that had been generated previously [6] . To add an epitope tag, four forward primers were used in sequential rounds of amplification to add a V5 tag to the cDNAs following the N-terminal signal sequence after amino acid 23. Using the same method, a Myc tag was added to the wild-type RS1 cDNA in the same position (primer sequences available from N.J.B. on request). Once the full-length fragments had been generated, each was cloned using the pcDNA5/FRT/TO-TOPO vector by TA cloning (Invitrogen). The full-length fragments were also digested from the pcDNA5 vector with PmeI and subcloned into pcDNA3.1 between the PmeI sites.
Generation of stable cell lines
The T-REx TM system (Invitrogen) was used to create stable cell lines with tetracycline-regulated expression of retinoschisin. Plasmid DNA was transfected into HEK-293 (human embryonic kidney-293) T-REx TM cells using FuGENE ® 6 (Roche) according to the manufacturer's instructions. Stable cells were selected for 14 days with hygromycin B (Invivogen) and blasticidin (Invivogen). HEK-293 T-REx TM cells expressing α 1 -antitrypsin were a gift from Lisa Swanton (University of Manchester). All HEK-293 T-REx TM cell lines were maintained in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10 % fetal bovine serum and 2 mM L-glutamine at 37
• C with 5 % CO 2 .
Cell culture and transfection COS-7 cells were maintained in DMEM supplemented with 10 % fetal bovine serum and 2 mM L-glutamine at 37
• C with 5 % CO 2 . For transfection, cells were seeded at approx. 80 % confluence into 6-cm-diameter dishes. Transfections were performed using PEI (polyethyleneimine) (Polysciences) at a PEI/DNA ratio of 2.5:1. Briefly, 4 μg of plasmid DNA was mixed with 500 μl of DMEM (serum-free) and 10 μl of PEI (1 μg/μl). For cotransfections, an equal amount of DNA was used for each construct. The transfection mixture was incubated at room temperature (20 • C) for 10 min before being added to the cells in 3.5 ml of DMEM plus 10 % fetal bovine serum.
Pulse-chase analysis
Cells were grown to 80 % confluence, and gene expression was induced by incubating cells for 16 h with 10 μg/ml tetracycline. Cells were deprived of essential amino acids for 30 min, incubated with radioactive methionine/cysteine protein labelling mixture (50 μCi/ml) (NEN) for a further 30 min and then the medium was replaced with DMEM with 10 % fetal bovine serum. Pulsechase analysis was carried out at 37
• C unless indicated otherwise. When DTT (dithiothreitol) was included in the pulse-chase, it was present at a final concentration of 5 mM. Cell suspensions were divided into aliquots of 1 ml, and, at the required times, cells and medium were separated and disulfide exchange was inhibited by the addition of 25 mM NEM (N-ethylmaleimide). Cells were lysed using lysis buffer [50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 2 mM EDTA, 0.5 mM PMSF and 1 % (v/v) Triton X-100]. Insoluble material was removed by centrifugation at 10 000 g for 1 min, and lysates were mixed with SDS to 1 % (w/v), boiled for 3 min and diluted 10-fold with lysis buffer. Clarified lysates were pre-cleared by incubation with Protein A-Sepharose for 30 min. Immunoisolation was carried out by incubation with Protein A-Sepharose and anti-V5 antibody (Invitrogen) for 16 h at 4
• C. Beads were washed three times with 100 vol. of RIPA buffer [1 % (w/v) deoxycholic acid, 0.1 % SDS, 1 % (v/v) Triton X-100, 50 mM Tris/HCl (pH 8.0), 500 mM NaCl and 0.5 mM PMSF] and resuspended in SDS/PAGE sample buffer [156.25 mM Tris/HCl (pH 6.8), 1.5 % (w/v) SDS, 10 % (v/v) glycerol and Bromophenol Blue]. Immunoisolation was repeated for whole-medium samples. For experiments where ER-Golgi transport was blocked, starvation and labelling were carried out at 37
• C and the chase period was carried out at 15
• C. For experiments where the proteasome was blocked, cells were pre-incubated for 1 h with 10 μM PSII (proteasome inhibitor II). PSII was added to cells throughout the starvation, labelling and chase period. For EndoH (endoglycosidase H) digestion, immunoisolated material was treated with 500 units of EndoH (New England Biolabs) at 37
• C for 30 min, according to the manufacturer's instructions, then analysed by SDS/PAGE (6-20 % gradient gels).
Western blot analysis
For Western blot analysis, whole-cell lysates were prepared by lysing transfected cells in 5× SDS loading buffer. For reducing SDS/PAGE, 5× SDS sample buffer was supplemented with 50 mM DTT. All samples were boiled for 5 min before loading on to SDS/polyacrylamide gels. Following electrophoresis, samples were transferred on to a nitrocellulose membrane. The membrane was incubated with the primary antibody [1:500 dilution for anti-retinoschisin [17] , 1:10000 for anti-V5 and 1:3000 for antimyc (c-Myc A-14, Santa Cruz Biotechnology)] for 1 h and then the relevant secondary reagent (horseradish peroxidase-labelled goat anti-rabbit IgG antibody for the anti-retinoschisin primary antibody or horseradish peroxidase-labelled Protein A for the anti-V5 and anti-myc antibodies) for 1 h. The signal was visualized using ECL (enhanced chemiluminescence) reagent (Pierce) and exposed to X-ray film (Fuji).
Sucrose gradient fractionation
Approx. 10 7 cells were lysed by vortex-mixing in sucrose gradient buffer [5 mM Tris/HCl (pH 7.5), 100 mM NaCl, 1 mM PMSF and 0.1 % Nonidet P40] following treatment with 25 mM NEM. Cleared lysates were applied to a continuous gradient of 9 vol. of 5 % (w/v) sucrose into 9 vol. of 25 % (w/v) sucrose, laid over 2 vol. of 50 % (w/v) sucrose in sucrose gradient buffer. Gradients were centrifuged at 40 000 rev./min for 16 h at 4
• C in a Beckman SW40Ti rotor and then separated into ten equal-volume fractions. Proteins were precipitated with 10 % (v/v) trichloroacetic acid and resuspended in SDS/PAGE sample buffer. For reducing denaturing gradients, cleared lysates were supplemented with 1 % (w/v) SDS and 10 mM DTT and boiled for 5 min before fractionation, and gradients contained 0.1 % SDS.
Immunofluorescence COS-7 cells were grown on coverslips and transfected as described above. At 48 h after transfection, cells were washed with PBS, fixed in ice-cold methanol for 10 min at − 20
• C and then washed again with PBS. Cells were then incubated at room temperature for 30 min with primary antibodies (1:300 dilution for anti-V5 antibody and 1:200 dilution for anti-myc antibody). After washing in PBS, cells were incubated at room temperature for 30 min with secondary antibodies [1:100 dilution for Alexa Fluor ® 594-conjugated anti-rabbit antibody (myc) and 1:100 dilution for Texas Red-conjugated anti-mouse antibody (V5)]. DNA was stained with DAPI (4 ,6-diamido-2-phenylinimide).
Co-immunoisolation
Cells were lysed in lysis buffer [1 % (v/v) Triton X-100, 50 mM Tris/HCl (pH 7.4), 150 mM NaCl, 2 mM EDTA and 0.5 mM PMSF]. Clarified lysates were pre-incubated with Protein A-Sepharose for 30 min to limit non-specific binding, before incubation with anti-myc antibody conjugated to agarose beads (Upstate Biotechnology) overnight at 4
• C. Beads were washed three times with lysis buffer before being resuspended and boiled for 2 min in SDS/PAGE sample buffer containing 50 mM DTT. Immunoisolated material was separated by SDS/PAGE (10 % or 6-20 % gradient gels as indicated in figure legends) and analysed by Western blot with the anti-V5 antibody.
Luciferase reporter assay
The p5xATF6-GL3 plasmid (UPR element luciferase reporter construct) was purchased from Addgene. The pRL-TK plasmid (control Renilla construct) was purchased from Promega. HEK-293 T-REx TM cells were seeded into six-well plates at 60 % confluence and then co-transfected with 50 ng of pRL-TK and 400 ng of p5xATF6-GL3 using Lipofectamine TM 2000 (Invitrogen) according to the manufacturer's protocol. Expression of the gene of interest was induced by the addition of 10 μg/ml tetracycline for 16 h. At 24 h post-transfection, cells were lysed, and the luciferase activity was quantified using the DualLuciferase Assay system (Promega).
Crystal Violet cell viability assay
HEK-293 T-REx
TM cells were seeded into six-well plates at 60 % confluence. Expression of the gene of RS1 was induced by the addition of 10 μg/ml tetracycline. Detached cells were removed 48 h after the addition of tetracycline by washing with PBS, and the remaining adherent cells were fixed in methanol at − 20
• C for 5 min. Cell nuclei were stained by the addition of 0.2 % Crystal Violet and 2 % (v/v) ethanol for 10 min before washing three times with PBS. The stain was solubilized in 0.1 % SDS, diluted 5-fold and quantified by measuring the absorbance at 540 nm.
RESULTS
Assembly of retinoschisin into an octamer occurs in the ER
It has been shown previously that retinoschisin exists as an octamer when isolated from cell culture medium or from tissues [8, 18] . To investigate the potential co-assembly of wild-type and mutant retinoschisin, we first needed to determine exactly where in the cell this oligomerization event occurred. To facilitate these studies, we constructed stable cell lines that overexpress retinoschisin in a tetracycline-inducible system. The cell lines constructed included wild-type and two disease-causing mutants, C59S and C110Y. The C59S mutant does not assemble and is secreted as disulfide-linked dimers, whereas the C110Y mutant is retained in the cell and does not assemble [8, 18] (see Figure 1A for a schematic diagram of disulfide linkages). To aid detection of all constructs, we included either a myc or a V5 epitope tag after the signal sequence. The inclusion of an epitope tag at this position does not interfere with retinoschisin localization, octamer formation or secretion [16] .
We first carried out a pulse-chase experiment to determine the kinetics of octamer formation. Cells expressing wild-type retinoschisin were induced with tetracycline and then pulselabelled. Retinoschisin was isolated and separated under nonreducing conditions. No radiolabelled protein was seen in the absence of induction with tetracycline ( Figure 1B, lane 2) . Several radiolabelled proteins were seen following induction. These include monomeric retinoschisin with the fastest mobility as well as slower migrating higher-order structures culminating with the slowest migrating band which corresponds to an octamer ( Figure 1B, lanes 3-8) . The monomer migrated faster through the gel under non-reducing than under reducing conditions ( Figure 1B , compare lanes 1 and 3), indicating that intrachain disulfide bonds formed rapidly in newly synthesized retinoschisin. The presence of octamers immediately after the pulse ( Figure 1B , lane 3) suggests that assembly occurs rapidly and possibly in the ER. When the medium samples were analysed, it was clear that only the octamer was secreted ( Figure 1B, lane 10) . Hence the cell line is capable of assembling octameric retinoschisin and contains an efficient quality control which prevents secretion of intermediates in the assembly pathway.
To pinpoint where in the cell assembly occurs, we took advantage of the fact that ER-Golgi transport can be inhibited if the temperature of incubation is decreased to 15
• C. To verify that transport was prevented, we analysed the maturation of EndoH-resistant glycans in α 1 -antitrypsin, an event that occurs following modification of oligosaccharide side chains in the Golgi apparatus [19] . We showed that the α 1 -antitrypsin becomes resistant to EndoH digestion after 60 min of chase when the cells are incubated at 37
• C, but remains sensitive to digestion when incubated at 15
• C (see Supplementary Figure S1 at http://www.BiochemJ.org/bj/425/bj4250275add.htm). When we carried out a similar experiment with wild-type retinoschisin, we saw assembly and secretion of the octamer into the medium when the cells were incubated at 37
• C ( Figure 1C,  lanes 1-5) . When the cells were incubated at 15
• C, assembly into an octamer still occurred, but this protein was not secreted ( Figure 1C, lanes 7-11) . The fact that the octamer still forms demonstrates that assembly must occur in a pre-Golgi compartment which is presumably the ER. TM stable cell line expressing myc-tagged wild-type retinoschisin was induced with 10 μg/ml tetracycline for 16 h. After a 30 min pulse, cells were chased for the times indicated. Chase was carried out at 37 or 15 • C as indicated. Aliquots of cell lysates and a sample of the cell medium at 120 min (120M) were subjected to immunoisolation with anti-myc antibody, and isolated proteins were analysed by SDS/PAGE (6-20 % gradient gel) under non-reducing conditions. Molecular masses are indicated in kDa.
Some retinoschisin mutants can escape the ER quality control
When we carried out a similar analysis to that for the wild-type protein, but with the C59S or C110Y mutant, we obtained quite different results (Figure 2) . As expected, the C59S mutant failed to form octamers, but was still secreted from cells predominantly as a dimer (Figure 2A) . The monomer formed intrachain disulfides as judged by its increased mobility compared with the fully reduced protein (Figure 2A, compare lanes 1 and 4) , indicating that the monomer at least had folded correctly. In contrast, the C110Y mutant did not form oligomers, and the monomer did not run as a single species, rather it formed a heterogonous mixture of redox forms that migrate between the fully reduced and fully disulfide-bonded forms ( Figure 2B , compare lanes 1 and 3, marked with an asterisk). No retinoschisin was present in the medium, indicating retention of this protein in the ER.
Figure 3 Retinoschisin octamers are not stabilized by non-covalent interactions
Cell lysates from tetracycline-inducible HEK-293 T-REx TM stable cell lines expressing V5-tagged wild-type (WT) or C59S mutant retinoschisin that had been induced with 10 μg/ml tetracycline for 16 h were subjected to sucrose gradient centrifugation under native or denaturing conditions. Following fractionation of the gradients, samples were precipitated with trichloroacetic acid and then separated by reducing SDS/PAGE before Western blotting with the anti-V5 antibody.
The lack of correct folding of the monomer clearly precludes assembly. Moreover, the signal for the monomer disappeared over the time course which could indicate degradation of this protein or formation of high-molecular-mass aggregates that do not enter the gel ( Figure 2B , top of resolving and stacking gel). To investigate whether the C110Y mutant did form highmolecular-mass disulfide-linked complexes, we also carried out the same pulse-chase experiment, but with DTT present in the pulse and chase to prevent disulfide formation ( Figure 2C ). Reduced retinoschisin was present throughout the time course and was again absent from the medium. Some disappearance of retinoschisin was observed at later time points ( Figure 2C , lanes 7 and 8), which indicates that some degradation occurred under these conditions. The C59S mutant removes one of the cysteine residues involved in the formation of an interchain disulfide bond. Sucrose gradient fractionation was carried out in order to determine whether non-covalent interactions were involved in the folding of retinoschisin ( Figure 3A) . The octamer would be expected to fractionate at the highest sucrose concentration, whereas the monomer would be expected to fractionate at the lower sucrose concentrations. The fact that the protein is present throughout the gradient argues that interchain disulfide-bonded intermediates in the assembly pathway do not form non-covalent interactions before the formation of the stabilizing disulfide. In support of this conclusion, when the C59S mutant was fractionated under native conditions, the protein was present at the lower sucrose concentrations ( Figure 3C ), indicating that no octamer assembled. There was a slight shift in the fractionation profile to a higher sucrose concentration when compared with the wild-type or C59S samples that had been reduced and denatured before fractionation ( Figures 3B and 3D ). This shift is likely to be due to the formation of disulfide-linked dimers that can form between Cys 40 in adjacent polypeptides ( Figure 1A ) [8] .
Wild-type retinoschisin can co-assemble with mutant proteins
Having established that assembly of the retinoschisin octamer occurs in the ER, we then wanted to determine whether wild-type and mutant protein could co-assemble when they were expressed together in the same cell. The approach we took was to co-transfect wild-type and mutant retinoschisin in COS-7 cells, a cell line that has been used previously to study retinoschisin co-assembly [16] . In these experiments, the wild-type protein included either a myc or a V5 epitope tag and the C59S or C110Y mutant contained a V5 epitope tag. To verify that the tags did not interfere with assembly and indeed that assembly and secretion of the octamer occurred in COS-7 cells, we separated the medium from transfected cells under non-reducing conditions and developed the resulting Western blot with an antibody against retinoschisin ( Figure 4A ). The wild-type V5 and wild-type myc formed octamers that were secreted from COS-7 cells. These octamers migrated slightly more slowly than the wild-type octamer, presumably due to the presence of the epitope tag ( Figure 4A ). We also established that we could co-transfect COS-7 cells with wild-type and mutant retinoschisin, so that they were expressed in the same cell. When cells transfected with either wild-type V5 and wild-type myc or wild-type myc and V5-tagged mutants were analysed by immunofluorescence, a signal for V5 and myc fluorescence was seen in the same cell ( Figure 4B ).
To determine whether co-assembly occurred, we co-transfected cells with wild-type myc and wild-type V5 or with wild-type myc and mutant V5. We included controls where cells were not transfected or were transfected with either wild-type myc or wildtype V5 on their own (Figures 4E and 4F) . We established that the transfections had been successful, by Western blotting the cell lysates before immunoisolation ( Figures 4C and 4D) . Following immunoisolation, no signal was seen in the cell lysate or medium from untransfected or singly transfected cells ( Figures 4E and 4F,  lanes 1-3) . A band corresponding to the size of retinoschisin was seen in the cell lysates for both the wild-type/wild-type and wildtype/mutant co-transfections ( Figure 4E, lanes 4-6) , indicating co-assembly within the cell. However, only wild-type/wild-type and wild-type/C59S co-transfection resulted in the appearance of co-assembled retinoschisin in the cell medium ( Figure 4F,  lanes 4 and 6) . These results clearly demonstrate that the C110Y and the C59S mutant can co-assemble with the wild-type protein in the ER.
The co-assembled wild-type and C59S molecules that were secreted could potentially exist as dimers, octamers or intermediates between these two oligomers. When cells were cotransfected with wild-type myc and C59S V5 mutant retinoschisin and the medium samples were immunoisolated with the antimyc antibody, several oligomeric intermediates were formed which cross-reacted with antibodies against the myc and V5 epitopes ( Figures 5A and 5B) . The presence of V5-reactive oligomers and assembly intermediates shows that the C59S mutant co-assembles with the wild-type protein, giving rise to the incorporation of the mutant protein into the oligomers. Moreover, the oligomers formed between the C59S mutant and wild-type proteins were not subject to ER quality control and were secreted.
The co-assembly of wild-type and the C110Y mutant retinoschisin could lead to a block in secretion of wild-type protein. To determine whether this was indeed the case, we looked to see whether wild-type protein was still secreted in these cotransfected cells. The cell lysates and medium samples from either singly transfected or co-transfected cells were analysed ( Figure 6 ). Wild-type protein was secreted from all cells that were transfected with wild-type protein, even in the presence of the C110Y mutant ( Figure 6B, lanes 2, 4 and 5) . Hence, whereas some wild-type protein must be retained in the ER, not all retinoschisin was prevented from being secreted when wild-type and the C110Y mutant were co-expressed. 2 and 3) , together (lane 4) or wild-type tagged with the myc epitope was transfected with V5-tagged C59S (C59S V5) or C110Y (C110Y V5) mutant retinoschisin (lanes 5 and 6). To check for expression, whole-cell lysates were separated by SDS/PAGE (10 % gel) under reducing conditions and analysed by Western blotting with antibodies against either the myc epitope tag (C) or the V5 epitope tag (D). Cell lysates (E) and cell medium (F) were subjected to immunoisolation (IP) with an agarose-conjugated antibody against the myc epitope. The resulting immunoisolated material was separated by SDS/PAGE followed by Western blotting with the anti-V5 antibody.
Retinoschisin mutants and the UPR
The time-course experiments carried out with the C110Y mutant retinoschisin-expressing cell line showed that the protein is retained in the ER and that there appears to be a disappearance of the protein over time. This could be due to the protein being degraded or forming larger aggregates that do not enter the SDS/polyacrylamide gel. To determine whether the protein is being degraded by ERAD (ER-associated degradation), we carried out a pulse-chase experiment, but this time included PSII to prevent ERAD ( Figure 6E ). The samples were separated under reducing conditions. No disappearance of the radiolabel was seen either in the presence or absence of PSII. These results indicate that the C110Y mutant retinoschisin was not subjected to ERAD, 4 and 8) . The cell medium was subjected to immunoisolation with an agarose-conjugated antibody against the myc epitope. The resulting immunoisolated material was separated by SDS/PAGE (6-20 % gradient gel) followed by Western blotting initially with the anti-myc antibody (A). The blot was stripped by brief treatment with 0.2 M NaOH before being reprobed with the anti-V5 antibody (B). Molecular masses are indicated in kDa.
even though it is retained in the ER. This is in contrast with the situation when the C110Y mutant is synthesized in the presence of DTT (see Figure 2C) . Hence formation of a high-molecularmass complex stabilized by disulfide bonds prevents the protein being degraded by ERAD.
The retention of the C110Y mutant and other mutant retinoschisin within the cell and the lack of degradation by ERAD is likely to induce a stress response that could lead to cell death. Such cell death could well contribute to the disease pathology alongside a lack of functional secreted protein. To assess whether the ER retention of retinoschisin caused an UPR, we first constructed cell lines that expressed untagged wild-type and mutant retinoschisin in tetracycline-inducible HEK-293 T-REx TM cells. A reporter assay was used, which involved co-transfecting cells with a firefly luciferase gene under control of the ATF6 (activating transcription factor 6) UPR element and a Renilla luciferase gene as a transfection efficiency control. The reporter assay system was validated by comparing UPR activity in untreated HEK-293 T-REx TM parent cells with that in tunicamycin-treated HEK-293 parent cells ( Figure 7A ). Tunicamycin caused a 30-fold induction of UPR activity in tunicamycin-treated cells compared with untreated cells. The luciferase reporter assay was then used on cells expressing wild-type or mutant retinoschisin. There was a slight, but significant, UPR (∼ 2-fold) when the expression of wild-type or the C59S mutant retinoschisin was induced with tetracycline ( Figure 7A ), indicating that the overexpression of even correctly folded protein causes a stress response. However, a larger increase in UPR activity (∼ 8-fold) was measured following induction of expression of the C110Y mutant retinoschisin ( Figure 7A ). To determine whether the UPR induced by mutant C110Y retinoschisin causes cell death, cell viability was investigated using a Crystal Violet assay ( Figure 7B ). Only 10 % of cells treated with tunicamycin were still viable after 48 h, whereas cell lines that had been induced with tetracycline to express wild-type, C59S and C110Y retinoschisin showed no decrease in viability after 48 h. These results demonstrate that, although a strong UPR is elicited by expression of a mutant retinoschisin, this does not lead to cell death. 
DISCUSSION
It is now well established that the absence of functional octameric retinoschisin causes the X-linked disease retinoschisis [20] . In the present study, we have shown that the assembly of this octameric protein occurs within the ER and that, for the wild-type protein, only the fully assembled molecule is secreted. Several intermediates in the assembly pathway are clearly present within cells, yet none of these is secreted, raising an interesting question as to how the ER quality-control system retains these unassembled forms. Intriguingly, the C59S mutant retinoschisin is secreted as a disulfide-linked dimer, demonstrating that the ER quality-control system does not recognize and retain this particular dimeric species. Retinoschisin forms two interchain disulfide bonds in the octamer, either between Cys 59 and Cys 223 or between two Cys 40 residues on adjacent polypeptides (see Figure 1A ) [12] . It is possible that the presence of Cys 59 causes retention of the wildtype protein until it is paired with Cys 223 . However, it has also been shown that a C223S mutant retinoschisin is also secreted from cells as a dimer [12] , so it is not simply the presence of Cys 59 that causes retention of the wild-type protein.
If retention was via a thiol-mediated process, as has been shown previously for IgM chain and adiponectin [21, 22] , then the single cysteine mutants would be expected to be retained, but they are not. Rather, it seems that, once the Cys 59 -Cys 223 disulfide bond is prevented from forming, then the cellular quality control does not retain the protein in the ER. It could be that the formation of the Cys 59 -Cys 223 disulfide bond occurs very early in the maturation of retinoschisin and that, once it is formed, it is retained, possibly due to the exposure of a motif that is recognized by an ER-resident protein.
Secretion can only occur once the octamer is formed, which would presumably mask the exposed motif. In the case of the mutants where the Cys 59 -Cys 223 disulfide bond is prevented from forming, the protein motif recognized by the ER quality-control system is never exposed, allowing secretion of a dimer stabilized by the Cys 40 -Cys 40 disulfide bond. Retinoschisis is an X-linked disease, so only one allele will ever be expressed in each cell as males are hemizygous, and X inactivation means that females have only one X chromosome active in each cell. Hence there are no natural situations where mutant and wild-type protein would be expressed in the same cell. One of the potential mechanisms to treat the disease would be to introduce a wild-type gene into affected individuals by gene therapy. However, for this to be successful, the wild-type protein would need to be secreted in a functional state when expressed in the presence of the mutant protein. Previously, a report has been published which indicated that co-expression of wild-type and mutant retinoschisin did not prevent secretion of the wild-type protein [16] . This study revealed that one particular retinoschisin mutant (R141H) did co-assemble with the wildtype protein and was secreted, suggesting that individuals with this mutation are not likely to benefit from this therapeutic approach. In the present study, we also show that the wildtype protein can be secreted when co-expressed with mutant retinoschisin. However, we also show that, in contrast with the previous study, the C59S mutant retinoschisin co-assembles with wild-type protein and that this co-assembled material is secreted. Remarkably, it is not just dimers of mutant and wild-type protein that are secreted, indicating that the mere presence of the C59S mutant subunit with multiple wild-type subunits is sufficient to subvert the ER quality control. It is highly unlikely that these partially assembled intermediates would be functional, so coassembly may prevent the expression of functional retinoschisin. In addition, the C110Y mutant retinoschisin, which is retained in the cell, also co-assembles with wild-type and retains some wildtype protein within the cell. It is likely that the level of expression of the wild-type protein relative to the mutant will determine how much protein is retained and consequently how much is secreted. It is difficult to predict the levels of expression of endogenous mutant protein with respect to ectopically expressed wild-type protein in a tissue, but our results should inform any potential gene-therapy strategy. It could be that sufficient wild-type protein will be secreted in tissues even in the presence of mutant protein to alleviate the symptoms of the disease. An alternative strategy would be to target expression to cells which do not normally express retinoschisin, such as Müller cells [23] .
Finally, we have demonstrated that the C110Y mutant retinoschisin that is retained in the ER fails to form the correct intrachain disulfide bonds, yet is stable and forms high-molecularmass aggregates that are stabilized by non-native interchain disulfide bonds. The consequence of a lack of turnover of this mutant coupled to the fact that it is not folded correctly is that it induces the UPR; however, this does not lead to a decrease in cell viability. As retinoschisin is normally expressed in photoreceptor and bipolar cells of the retina, any induction of programmed cell death would have drastic consequences for vision. Photoreceptor cell death does occur in retinoschisis [24] , but this is thought to follow the formation of cysts and retinal splits [14, 15] , which occur first, a phenotype that can be explained more realistically by a lack of cell adhesion. Hence our results support the concept that the disease pathology is caused simply by a lack of secretion of functionally active retinoschisin [8, 18] .
AUTHOR CONTRIBUTION
Lindsay Gleghorn carried out all of the experimentation. Dorothy Trump provided intellectual input into the design of the experiments. Neil Bulleid provided intellectual input and wrote the paper.
